Electropharmacology sells SofPulse to ADM:
This article was originally published in Clinica
Executive Summary
Electropharmacology has sold the assets in SofPulse, a palliative pain treatment device, to ADM Tronics, a Northvale, New Jersey company making its first entry into the US devices market. The SofPulse divestiture is the first stage in Pompano Beach, Florida-based Electropharmacology's plan to restructure around the Pulsed Electromagnetic Signals (PEMS) technology, aimed at "large markets such as cancer, inflammation and tissue regeneration". ADM plans to expand distribution of SofPulse in the US and to target present distributors of its Sonotron device outside the US. SofPulse last year generated revenues of $1.5 million.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.